Motor Sparing Supraclavicular Block
Motor Sparing Supraclavicular Brachial Plexus Block (MS-SCBPB): A Randomized Controlled Trial
Cairo University
44 participants
Sep 25, 2023
INTERVENTIONAL
Conditions
Summary
This study aims to compare MS-SCBPB and SCBPB in the duration of postoperative analgesia, time to first analgesic request (VAS ≥40 mm), pain scores, motor power, and side effects.
Eligibility
Inclusion Criteria3
- Patients scheduled for upper limb surgeries under supraclavicular brachial plexus block
- American Society of Anesthesiologists (ASA) status I and III
- between ages of 18 and 60 years
Exclusion Criteria8
- Bleeding disorders with INR \> 1.5 and/or platelets \< 100,000/mm3
- infection at the injection site
- Allergy to local anesthetics
- Severe cardiopulmonary disease (≥ASA IV)
- Diabetic or other neuropathies
- Motor disorders
- Patients receiving opioids for chronic analgesic therapy
- Inability to comprehend visual analogue scale (VAS).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Block will be performed in semi-sitting position with head tilted to the opposite side of injection site. linear probe (4-12MHz) (Mindray Digital Ultrasonic Model DP-10 "SN 6N-49005130" 2014-09. SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO.LTD) will be placed parallel to the clavicle in the supraclavicular fossa visualizing the subclavian artery is seen beating above the first rib. A volume of 2 mL lignocaine 2% will be infiltrated subcutaneous before the block. A 20-gauge needle will be advanced in plane aiming to the corner pocket towards the deeper portion of the brachial plexus at the angle between the first rib and the subclavian artery, 10 mL of drug will be injected. Then, the needle will be retracted and advanced at a shallower angle, aiming toward the superficial plexus after negative aspiration another 10 ml will be injected, total drug injected 20 ml (18 mL of drug will be injected with addition to 8mg dexamethasone (2ml))
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06074471